Product menu

VISUAL OF AN OLDER MALE PATIENT

Learn more about the risk of RSV infection

RSV is a common and contagious virus that typically produces mild, cold-like symptoms in adults.1,2 However, older adults, including those with certain comorbidities*, are at risk of severe RSV infection.1-3

* Chronic heart or lung disease, or adults with weakened immune systems.

IMAGE OF A FEMALE PATIENT

RSV fast facts

  • RSV-A and RSV-B subtypes co-circulate in Canada.4
  • RSV is very contagious. RSV virus has a basic reproduction number (R0) of 3.0.5,6
  • People can get repeat RSV infections, and individuals of any age can be infected.7
  • RSV infection can happen at any time of the year.8 It follows a seasonal pattern, and in Canada, a wave of increased activity usually occurs from fall to mid-to-late spring.1

Severe outcomes of RSV can include:1,3

ICON OF LUNGS WITH AN INFECTION

Lower respiratory tract infections, such as pneumonia

ICON OF A HOSPITAL BED WITH THE HOSPITAL PLUS SYMBOL

Hospitalization

ICON OF A PERSON AND A TRIANGLE WITH AN EXCLAMATION POINT

Death

AREXVY is not indicated for the treatment of RSV or its complications, such as hospitalizations.

Age-related decline in immunity describes a progressive decline in immune function that makes older adults more susceptible to numerous infections, including RSV.9

What is the impact of RSV in older adults?

Each year in the United States, approximately 177,000 older adults are hospitalized, and an estimated 14,000 die due to RSV.10

The mortality rate in patients ≥65 years hospitalized with RSV has been shown to be 1 in 9 patients.11*

ICON OF A HOSPITAL BED WITH THE HOSPITAL PLUS SYMBOL

AREXVY is not indicated for the treatment of RSV or its complications, such as hospitalizations.

* 30-day all-cause mortality. Retrospective cohort study from Ontario, Canada. Hospitalization data collected from the 2010–11 to 2018–19 respiratory virus seasons.

Find out more about the burden of RSV in Canada by clicking the link below.

LEARN MORE

Infection with RSV can put older adults, including those with certain comorbidities, at risk for severe outcomes1-3,12

Adults aged 60 years and older are at high risk for severe outcomes from RSV infection, including those with:1-3

ICON OF A PERSON WITH A MEDICAL MASK

Certain underlying conditions, including chronic lung or heart disease

ICON OF A SHIELD AND A VIRUS

Weakened immune systems

Among older adults in New York City and Rochester, New York, chronic conditions were shown to increase the risk of RSV-related hospitalization13*†

ICON OF INFECTED LUNG

Asthma
2.3 to 2.5x more likely
(95% CI: 1.67–3.09, 0.81–7.86, respectively)

ICON OF INFECTED LUNG

COPD
3.5 to 13.4x more likely
(95% CI: 2.63–4.69, 4.29–41.98, respectively)

ICON OF A HEART

CHF
5.9 to 7.6x more likely
(95% CI: 4.07–8.46, 2.43–23.93, respectively)

2 BLOOD DROPLETS LABELLED 1 AND 2

Diabetes
2.4 to 6.4x more likely
(95% CI: 1.82–3.04, 2.06–20.17, respectively)

AREXVY is not indicated for the treatment of RSV or its complications, such as hospitalizations.

CHF = congestive heart failure; COPD = chronic obstructive pulmonary disease.
* Estimated annual RSV infection incidence rate ratio among people with each comorbidity vs. those without it, in the surveillance area population of adults aged ≥65 years (or 60–79 years for CHF).
† AREXVY is not indicated for asthma, COPD, CHF, and/or diabetes.

CHECKMARK ICON

Recommendations

Review recommendations on RSV vaccination for adults aged ≥60 years.12,14-16

LEARN MORE

SPEECH BUBBLES ICON

Start the conversation about RSV risk with your patients aged 60+ years

Older adults aged ≥60 years may receive a single dose of RSV vaccine, using shared clinical decision-making.12

LEARN MORE

References:

  1. Government of Canada. Respiratory syncytial virus (RSV): for health professionals. Available at: https://www.canada.ca/en/public-health/services/diseases/respiratory-syncytial-virus-rsv/health-professionals.html. Accessed February 10, 2023.
  2. Centers for Disease Control and Prevention. Respiratory syncytial virus infection (RSV): for healthcare providers. Available at: https://www.cdc.gov/rsv/clinical/index.html. Accessed September 28, 2023.
  3. Centers for Disease Control and Prevention. Respiratory syncytial virus infection (RSV): older adults. Available at: https://www.cdc.gov/rsv/high-risk/older-adults.html. Accessed February 22, 2023.
  4. Chadha M, et al. Human respiratory syncytial virus and influenza seasonality patterns—Early findings from the WHO global respiratory syncytial virus surveillance. Influenza Other Respir Viruses 2020;14:638–646.
  5. Ontario: Ministry of Health. Respiratory Syncytial Virus. Available at: https://www.ontario.ca/page/respiratory-syncytial-virus. Accessed November 3, 2023.
  6. Public Health Ontario. At a glance: Key features of influenza, SARS-CoV-2 and other common respiratory viruses. Available at: https://www.publichealthontario.ca/-/media/documents/ncov/ipac/2020/09/key-features-influenza-covid-19-respiratory-viruses.pdf?sc_lang=en. Accessed September 15, 2023.
  7. Government of Canada. Respiratory syncytial virus (RSV): symptoms and treatment. Available at: https://www.canada.ca/en/public-health/services/diseases/respiratory-syncytial-virus-rsv.html. Accessed February 10, 2023.
  8. Hamid S, et al. Seasonality of respiratory syncytial virus – United States, 2017-2023. MMWR 2023;72(14):355-361.
  9. Stephens LM, et al. Considerations for a respiratory syncytial virus vaccine targeting an elderly population. Vaccines (Basel) 2021;9(6):624.
  10. Centers for Disease Control and Prevention. Increased interseasonal respiratory syncytial virus (RSV) activity in parts of the southern United States. Available at: https://emergency.cdc.gov/han/2021/han00443.asp. Accessed June 29, 2022.
  11. Hamilton MA, et al. Predictors of all-cause mortality among patients hospitalized with influenza, respiratory virus, or SARS-CoV-2. Influenza Other Respir Viruses 2022;16:1072-1081.
  12. Melgar M, et al. Use of respiratory syncytial virus vaccines in older adults: recommendations of the Advisory Committee on Immunization Practices—United States, 2023. Morb Mortal Wkly Rep 2023;72:793–801.
  13. Branche AR, et al. Incidence of respiratory syncytial virus infection among hospitalized adults, 2017-2020. Clin Infect Dis 2022;74(6):1004–1011.
  14. Government of Canada. Respiratory syncytial virus (RSV): Canadian Immunization Guide. Available at: https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/respiratory-syncytial-virus.html. Accessed January 26, 2024.
  15. American Diabetes Association Professional Practice Committee. 4. Comprehensive medical evaluation and assessment of comorbidities: Standards of Care in Diabetes – 2024. Diabetes Care 2024:47(Suppl.1):S52–76.
  16. Global Initiative for Chronic Obstructive Lung Disease 2024 Report. Available at: https://goldcopd.org/wp-content/uploads/2024/01/GOLD-2024_v1.2-11Jan24_WMV-1.pdf. Accessed February 8, 2024.

Trademarks are owned by or licensed to the GSK group of companies.

©2024 GSK Group of companies or its licensor.

104605 | 07/24

Open cookie banner
Hide cookie banner